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Abstract: Health economics is extensively used by reimbursement agencies to make 
decisions on whether to adopt new medical technologies.  It is also used by the healthcare 
industry as an aid to decision making during product development. This paper proposes 
that academic healthcare technology transfer could also benefit from adopting health 
economics. 
The study investigated the knowledge and attitudes of academic staff involved 
in developing and transferring healthcare technologies. The participants had little or no 
prior knowledge of health economics; however, the majority reported that this method 
had the potential to aid development and commercialisation.  The innovations developed 
by the workshop attendees and their commercialisation plans were of a type that could 
potentially benefit from cost-effectiveness calculations.   
Health Economics has the potential to make a valuable contribution to academic 
healthcare innovation. Research is required to develop this method further and ensure that 
it can be successfully applied in academia. 
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Stephen P Morgan PhD is Professor of Biomedical Engineering. Since 1992 he has been 
researching novel optical techniques for imaging and spectroscopy of tissue. In 1998 he 
was awarded a prestigious EPSRC Advanced Fellowship to perform research in 
biomedical optics. His research is in two main application areas; firstly, the development 
of novel optical techniques for applications in regenerative medicine. This research has 
involved applying techniques such as ultrasound modulated optical tomography, 
polarized light imaging and machine vision to 3D tissue growth in bioreactors. Secondly, 
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1. Introduction 
There is a growing consensus across the world that innovation and technology play a key 
role in ensuring long-term sustainable economic growth. These issues become even more 
important in times of economic crisis. In Europe, extensive financial and policy support 
has been provided to bring innovations to market across the whole of the European Union 
(EU) and the individual European nations (CEC, 2009). In the USA, a series of strategies 
have been initiated to maintain its competitive status in innovation (Bendis and Byler, 
2009). In the UK, it is a long-term policy of the government WR EXLOG DQ µLQQRYDWLRQ
QDWLRQ¶, to encourage knowledge transfer and to increase the link between universities 
and business (DIUS, 2008). Innovation by academic institutions plays an important role 
in achieving these government ambitions.  
A current global economic downturn compels academic researchers and 
research funders to place even greater emphasis on the potential social and economic 
impact of innovation to the nation. The response to this by the Research Councils within 
the UK (RCUK), one of the main UK academic research funders, has been to stipulate 
that an impact statement is included in any funding application. Taking the Engineering 
and Physical Sciences Research Council (EPSRC) as an example (EPSRC, 2009a, b), 
funding applicants are asked to set out the potential impact of their proposed research in 
terms of: economic potential; healthcare and quality of life (QoL) improvements; new 
skills or the contribution to the advancement of knowledge. Although scientific quality of 
the research is still the primary criterion for funding, research councils are increasingly 
focusing on the potential impact of innovations. Issues such as these, combined with the 
importance academia now places on commercialising innovations, means that effective 
methods are required, which allow both researchers and funders to demonstrate and 
evaluate the impact of the innovations developed by academic institutions.  
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Of all the industry sectors, healthcare is the fastest growing and plays a 
significant role in society as well as the economy. The World Health Organization 
(WHO) has called for innovative health technologies with the aim of identifying and 
evaluating innovative medical devices to make quality healthcare accessible to the whole 
world. The EU is launching a joint programme from 2010 to 2013 on improving health 
technology assessment cooperation among European countries. A particular strength of 
the UK is research into world-leading healthcare technologies, which are highly 
innovative and knowledge-based (TSB, 2009). The National Health Service (NHS), the 
main healthcare service provider and principal healthcare technology purchaser in the 
UK, has taken strategic actions to promote innovation and adoption.  As Darzi recently 
identified, ³,QQRYDWLRQLQWKH1+6LVQ¶WMXVWDOX[XU\LW¶VDQHFHVVLW\LIZHZDQWWRKDYHD
health service that provides high quality care for SDWLHQWV¶HYHUHYROYLQJQHHGV´ (Darzi, 
2009).  One recent initiative is the National Innovation Centre (NIC), launched as part of 
the NHS Institute for Innovation and Improvement, aims to encourage innovation and 
speed up adoption of innovation into the NHS. The UK Government also provides a 
range of programmes to encourage innovation by providing investment aimed at health 
research (TSB, 2009). 
One criticism that has historically been levied at the UK is that it is good at 
research but poor at its exploitation (Lambert, 2003; Sainsbury, 2007). However, recent 
initiatives from central government, national and regional organisations and universities 
have improved this situation. According to the Sainsbury Review (Sainsbury, 2007), 
which is based on metrics such as attracting external investment and producing spin-out 
companies, UK universities are now performing at an equivalent level in technology 
transfer as their top US counterparts. The Government has developed a number of 
schemes to encourage the technology transfer and increase the impact of academic 
innovations (DIUS, 2008). For example, the Higher Education Innovation Fund 
programme (Sainsbury, 2007) was set up in 2001 with the aim of encouraging technology 
transfer by academia and a number of initiatives are organised by the RCUK including 
the knowledge transfer portal, launched in February 2009 (BBSRC, 2009), which 
provides full support and guidance for university-business interaction activities. There is 
substantial evidence, therefore, of the increasingly important role that universities are 
playing in the national and local economy. The key challenge for successful technology 
transfer is identifying potentially profitable and commercially successful technologies. 
There is a need for methods and tools to enable better decisions to be made when 
identifying technologies that are likely to have the greatest impact.   
In this paper, we consider innovation by academic institutions in the area of 
healthcare technology. We propose that a health economic approach can be effectively 
used to assess the potential value of a healthcare technology at an early stage in the 
development process. We suggest that this method can be used by a variety of 
stakeholders, including technology transfer officers and research funders, to identify 
those technologies that will have the greatest impact, from a clinical cost-effectiveness 
perspective. Health economics is a readily available technique for healthcare technology 
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evaluation and it has been widely applied by healthcare authorities and the healthcare 
industry, however it is a relatively new approach for academia.  
Health economics provides an effective method for evaluating the cost-
effectiveness of healthcare technology from the healthcare purchaser perspective. This 
type of economic evaluation is becoming increasingly popular worldwide when making 
decisions on whether to adopt new healthcare technologies (Kobelt, 2002). In the UK, the 
NHS routinely applies cost effectiveness analysis for health technology assessment of 
treatments. This type of analysis is carried out by: the National Institute for Health and 
Clinical Excellence (NICE) of England and Wales; Quality Improvement Scotland; and 
the Department of Health, Social Service and Public Safety Northern Ireland. Health 
economics has also been successfully used as a marketing tool by the healthcare 
technology industry.  
In recent years, as well as using it to demonstrate the value of mature products to 
healthcare providers, the healthcare industry applying health economics as early as 
possible during the product lifecycle. The aim of this approach is to improve the 
development decisions made and increase the likelihood of the product being 
commercially successful (Craven et al., 2009; Cosh et al. 2007). We propose that this 
concept could also be applied to the assessment of the value of healthcare technology 
innovations developed by academia, for example at the early stages of either a research 
funding application or during technology transfer. 
The need for wider education in Health Technology Assessment amongst non-
specialists is evidenced by its relevance to training aimed at clinical engineers and 
biomedical technicians (Menon 1993, Elder and Corrin, 1995, Gilly, 2007). Inventors of 
mobile devices and software with clinical applications also need to be aware of HTA 
processes (Craven, 2006). HTA is beginning to find its way into university engineering 
courses. 
However, developing Health Economic Models is a complex process and as a 
result, formal health economic tools are often only employed by professional health 
economists on behalf of healthcare authorities or large pharmaceutical and medical 
device companies. There is a need, therefore for a simple and easy to use cost-
effectiveness analysis tool which can be effectively applied by companies with fewer 
resources as well as healthcare innovation purchasers.  
 
An early stage tool to aid decision making based on health economics has 
recently been developed by the UK-based EPSRC funded Multidisciplinary Assessment 
of Technology Centre for Healthcare (MATCH). The tool has been designed for people 
that have little or no experience of health economics. It is aimed at the healthcare 
technology industry and the NHS as a means of accelerating the adoption of innovative 
technology.  
The aim of this paper is to investigate how health economics may contribute to 
the evaluation of healthcare innovations developed in academia. We present an overview 
of the theory of Health Economics and the background to the development of the 
MATCH health economic tool. A secondary aim is to investigate how this approach may 
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be used by academic researchers during the development or technology transfer of 
healthcare innovations by means of a questionnaire study. 
 
2. Application of Health Economics to healthcare innovation in 
academia 
2.1 Health Economics and a Health Economic Evaluation Tool  
What is Health Economics? 
The study of health economics arises from the confliction between the finite resources 
available and the demanding requirements from the public for better healthcare. Health 
economics therefore deals with issues of reasonable resource allocation, making choices 
about competing interventions with the aim of maximising value-for-money. A health 
economic evaluation compares costs and benefits of two (or more) healthcare 
interventions (Fox-Rushby and Cairns, 2005). Thus, economic evaluation compares one 
intervention relative to another or several alternatives in terms of cost and benefit 
differences. There are different types of economic evaluation methodologies designed to 
assess the cost-effectiveness of different interventions, e.g. cost-minimization analysis, 
cost-consequence analysis, cost-effectiveness analysis, cost-utility analysis and cost-
benefit analysis (Kobelt, 2002). Cost-utility analysis is currently employed by NICE for 
healthcare technology appraisal (NICE, 2008). It also forms the theoretical basis of the 
MATCH health economic evaluation tool.  
In health economic evaluation, the costs involved in the treatment are measured 
in terms of money, while the outcome of the healthcare intervention can be measured in 
different ways within different contexts for different comparative aims. The most 
frequently used measure of the health outcome is the quality-adjusted-life-year (QALY), 
which measures the medical consequences in terms of quantity (life years) and quality of 
life (utility) gained through a treatment, i.e. QALY = Number of years spent in a 
particular health state x the Utility of that health state. The utility is a numerical measure 
of a particular health state between 0 and 1, where 0 represents dead and 1 is perfect 
health (Kobelt, 2002).   
The result of a health economic evaluation is represented by the incremental cost 
effectiveness ratio (ICER), i.e. the differences in costs divided by the differences between 
the effects of different clinical interventions. For a cost-utility analysis, the clinical effect 
is measured using the QALY and the ICER is therefore expressed in the following form;  
 
QALY)( Effects in Difference
Cost)( Costs in Difference
          
Treatment Old of Effect - Treatment New of Effect
Treatment Old of Cost - Treatment New of CostICER
'
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The ICER can be displayed on a cost-effectiveness plane as shown in Figure 1 
which represents the difference in outcome on the horizontal axis and the difference in 
cost on the vertical axis. The cost-effectiveness plane shows four types of outcomes 
arising from the incremental differences between the new and incumbent treatments. 
Quadrant I represents the situation when the new treatment should be rejected as it is less 
effective and more expensive. Quadrant III represents the opposite situation; it should be 
accepted, as the new treatment is more effective and less expensive. Quadrants II and IV 
represent situations where there is a trade-off between costs and benefits. Due to the 
preference of the healthcare decision makers for more effective treatments, more focus is 
given to Quadrant II in which the innovative healthcare technology brings more benefits 
but costs more money than the existing situation. Decisions on whether the improvements 
in outcome are worth the additional cost can then be made based on a willingness-to-pay 
(WTP) threshold. WTP represents the maximum level of acceptance of the healthcare 
purchasers for the extra costs caused by the new technologies. If the ICER lies below the 
WTP it has a higher probability of being accepted, for example point A in Figure 1. If the 
ICER lies above the WTP it will be rejected e.g. point B in Figure 1. In the UK, NICE 
generally sets the WTP threshold at £25K-£30K/QALY (NICE, 2008). 
The aim of a health economic evaluation is to aid decision making based on a 
variety of data, which is analyzed on the basis of a health economic model. The most 
frequently used modeling methodologies in health economics are a decision tree model 
and a Markov model (Kobelt, 2002; Fox-Rushby and Cairns, 2005). A decision tree 
model depicts the possible events and outcomes of the treatment and is considered to be 
the simplest economic model, while the Markov model is more powerful at modeling 
chronic conditions with relapse symptoms. The MATCH health economic evaluation tool 
is based on the decision tree model. 
 
The MATCH Health Economic Evaluation Tool 
MATCH has developed a health economic evaluation tool using Microsoft Excel, which 
is designed for use by people who are not expert in health economics. The tool is based 
on cost-XWLOLW\ DQDO\VLV ZKLFK IROORZV WKH 1,&( µUHIHUHQFH FDVH¶ HFRQRPLF HYDOXDWLRQ
approach (NICE, 2008). A binary decision tree model is employed to compare the 
differences in costs and benefits between the innovative healthcare technology and the 
alternative, as shown in Figure 2. Under more complicated situations, a more complicated 
decision tree model could be constructed with more branches followed by more than two 
health outcomes. But for the purpose of simplifying the problem and considering the 
broader spectrum of users of the tool, the MATCH tool employs a simple binary decision 
tree structure. 
Reading from left to right in Figure 2, the decision tree starts from the square 
decision node, and the two branches originating from the decision node represent the 
innovative and existing healthcare technologies. The green circle decision node 
represents the possible actions for each condition. The decision tree ends at the red 
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triangle end node. The tool considers two possible outcomes with the treatment, i.e. 
healthy or not healthy. The health status is expressed with utility values and the final 
health benefits are measured with QALYs.  
Figure 3 displays a screenshot of the tool developed within Microsoft Excel. The 
tool is described in more detail elsewhere (Craven et al., 2009). The top left shows the 
cost-effectiveness plane displaying the ICER and WTP threshold. The decision tree is 
shown on the right hand side and data is input in the centre panel. Scroll bars (bottom 
left, figure 3) can be used to investigate the sensitivity of different parameters. The tool 
also provides a breakeven analysis, which is designed for the healthcare manufacturer to 
anticipate the potential profitability (screen not shown here). 
The data needed for the tool include the direct/indirect costs, the utility of the 
final health states after the treatment and the probability of each event. This information 
can be obtained through clinical trial, expert opinion or a literature review. At an early 
stage of product development, in the absence of established data, a developer could 
simply use a best estimate.  
 
Figure 1 The Cost-effectiveness plane. Point A is cost effective, while point B is not 
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Figure 2 Decision tree structure of the MATCH Health Economic Evaluation Tool 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 The MATCH Health Economic Evaluation tool 
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2.2 Stage gate model 
A stage gate model (Cooper, 2009) is frequently used by industry in the product 
development process and has been suggested as an appropriate model for medical device 
development (Pietzsch et al, 2009). This takes a product from concept through to market. 
At specific points in the developmHQWSURFHVVµJDWHV¶GHFLVLRQVDUHPDGHRQZKHWKHUWR
continue or cease with the development. At different stages tools can be used to aid 
decisions. An example is shown in Figure 4 where a business product passes through the 
stages from the initial concept until launch. Healthcare technologies are usually assessed 
using health economic approaches at a late stage in the development process, e.g. Stage 4 
of the post-development testing stage in Figure 4. Within MATCH we have worked with 
industry to embed this type of assessment approach earlier in the development process 
(Craven et al., 2009; Cosh et al., 2007), e.g. Stage 2 of the pre-development investigation 
stage in Figure 4. Clearly at an early stage in the development process clinical trials of a 
product will not have taken place, however, it should be possible to estimate the 
performance of a product in order to understand its potential cost-effectiveness. For 
example if an optimistic estimate of the performance is made and the product is still not 
shown to be cost-effective then questions about future investment should be raised.  
We propose that a similar stage gate model can be constructed to describe the 
healthcare technology development process in academia and its subsequent technology 
transfer. As shown in Figure 5, the process is divided into 6 stages, i.e. concept, research 
development (research funding application), research commercialisation development 
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(technology transfer funding application), industrial development, market, and 
reimbursement. The process shown in Figure 5 has a similar form to that shown in Figure 
4 but with the focus on showing the stages of embedding the health economic approach 
into the academic innovation development process.  
The first stage shows an initial idea for a healthcare innovation, a decision then 
needs to be made as to whether a research funding application should be made (gate 1 of 
Figure 5). After funding and its associated research, a decision then needs to be made 
within the academic institution as to whether to attempt to commercialise the product 
(gate 2 of Figure 5). If a positive decision is taken, then funding can be sought to transfer 
the technology (Lambert, 2003; Sainsbury, 2007). This could be done in several ways, 
e.g. by obtaining industrial investment, by setting up a collaborative research partnership, 
by licensing the product to the companies or by formation of a spin out company. 
Successful transfer of the technology into an industrial environment then results in the 
product development process following a similar stage gate model as described in Figure 
4. An additional reimbursement stage is added, which is where the decision is made by 
healthcare providers on whether to adopt the technology.  
At each gate in the product development process a health economic tool can be 
used to predict what the likely adoption decision of a healthcare provider would be. 
Clearly at an early stage the data supplied to the model will be less accurate, e.g. carrying 
out cost-HIIHFWLYHQHVVDQDO\VLVZLWKHVWLPDWHGGDWDDW µJDWH¶RI Figure 5, but this will 
improve as the product moves through the development process, e.g. in-house trial data 
FRXOGEHXVHGDWWKHµJDWH¶DQGFOLQLFDOWULDOGDWDFRXOGEHXVHGDWµJDWH¶RIFigure 5.  
There are several advantages to this approach. Firstly it allows both academics 
and technology transfer staff to assess which innovations are likely to have the greatest 
impact on healthcare. This is often useful when technology transfer offices are inundated 
with innovations. Secondly, as previously discussed, there is an increasing demand from 
research funders for applicants to demonstrate the value and impact of new technologies 
and this approach offers the potential to achieve this. Finally a health economic approach 
can be used to fulfill the demand from potential investors for technology transfer staff to 
demonstrate the value of the innovation.  
 
Figure 4 A generic stage gate model depicting the business process from idea to launch 
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Figure 5 Academic innovation development stage gate model 
 
 
 
 
 
 
 
 
2.3 Case Study Examples 
The MATCH HE tool has been successfully applied to the development of a number of 
real medical devices. This was in collaboration with the NHS National Innovation Centre 
who are assisting Small and Medium Enterprises, many of which are university spin-out 
companies, to self-assess the value of their innovations at an early stage in the R&D 
process. Examples of novel devices included an optical blood glucose meter and a 
dynamic oxygen therapy system. 
 The findings from these case studies demonstrated a number of benefits for the 
product developer. It helped them identify data requirements essential for building the 
value proposition for their innovation. Crucially, this data included not only costs, but the 
outcomes measures that the health provider would focus on when making a purchasing 
decision. More generally, by using the tool, the innovators were stimulated to formally 
articulate the positioning of their device in the patient pathway; it also allowed the 
innovator to directly compare its benefits in relation to the existing alternative technology 
i.e. their competitor. Use of WKHWRRODOVRHQFRXUDJHGµVWDJH-gatHWKLQNLQJ¶Ey identifying 
the data that would be required to make informed decisions at future points in the 
development process, a process that has been shown to benefit new product development 
(Cooper and Kleinschmidt, 1991; Page, 1993).  
 
For a full description of these early-stage device evaluations see Craven et al., 2009.  
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3. Survey of decision making in healthcare technology development 
in academia 
3.1 Health Economics Workshop 
A workshop on Health Economics and the MATCH Health Economic tool was held at 
the University of Nottingham on the 19th June 2009. The aims of this workshop were 
twofold. Firstly, to introduce the theory of health economics and the MATCH HE tool to 
academics working on healthcare innovations. Secondly, to investigate the nature of 
healthcare innovation with academia in order to determine to what extent health 
economics could contribute to this.   
The workshop was advertised via email to all staff at the University as 
µ$VVHVVLQJ DQG GHPRQVWUDWLQJ WKH YDOXH RI \RXU +HDOWKFDUH 7HFKQRORJ\¶ ,W ZDV
suggested that it may be relevant to academics, researchers and research students 
developing innovative healthcare technologies and technology transfer officers. A total of 
28 staff attended the workshop, which lasted for approximately 3 hours. 
The workshop, which was conducted by the authors, began by introducing 
health economics and describing how this method was applied in the UK. Some key 
concepts in cost-effectiveness analysis were presented in detail such as utility, QALY, 
and the cost-effectiveness plane. Participants were also given details of additional sources 
where information on data collection could be found.  
Following the health economics presentation, the MATCH HE tool was 
described and then demonstrated using a real case example from the area of orthopaedic 
technology, and the data required for the calculations identified. All the attendees were 
then provided with the opportunity to perform the case study example themselves by 
installing the tool software on their own laptop computers. The authors were on hand 
throughout to provide any assistance that the attendees required.   
Following the workshop all attendees were asked to complete a questionnaire 
containing a mixture of both open and closed questions. The questionnaire covered a 
QXPEHURIWRSLFVUHJDUGLQJWKHDWWHQGHHV¶KHDOWKFDUHUHODWHGUHVHDUFKLQWHUHVWVLQFOXGLQJ 
x Background information about the attendees 
x The types of healthcare innovations they were involved in and the potential 
impact of these 
x Their previous knowledge and experience of health economics 
x Their current plans for commercialising and demonstrating the value of their 
innovations  
x Their priorities when initiating innovative product development 
x Their views on the priorities of research funders 
x Their views on the MATCH HE tool 
In addition, the questionnaire also asked the attendees to provide feedback on the 
workshop. 
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3.2 Results of Questionnaire Study 
The main results are described below following the order of the questions in the 
questionnaire. 
 
Question 1: Please briefly describe your role within the university. 
Question 2: Please briefly describe your healthcare related research interests. 
Of the 28 attendees, nineteen participants returned a completed questionnaire. 
The majority of the respondents held academic teaching positions at the university such 
as professor (1), reader (6) and lecturer (3). A number of people with research only 
positions also attended including both postgraduate students (2) and post-doctoral 
researchers (4) and a research nurse (1). The non-academic attendees consisted of 
knowledge transfer specialists (2). All the respondents have healthcare research related 
background.     
 
Question 3: Please select the potential impact of your research on healthcare. 
The most common response tRWKLVTXHVWLRQZDVWKDWLWZRXOGEHµPRUHHIIHFWLYH
WKDQSURGXFWV FXUUHQWO\RQ PDUNHW¶ ZLWK WKH PDMRULW\RI WKH DWWHQGHHV  VHOHFWLQJ
this option (Figure 6). Eleven of the respondents believed that their innovation would 
offer an improvement over current clinical practice, either a radical improvement (5) or 
an incremental one (6). Only 4 participants reported that their innovation would be 
cheaper than the products currently on the market. Other reported potential impacts 
included changing the clinical pathway (4) and improving patient safety (6).   
 
Question 4: Is there a plan to commercialise your academic innovation? 
Question 5: How do you plan to transfer your knowledge? 
The majority (13/19) of the respondents expressed that they planned to 
commercialise their research outcomes. When asked about how they were planning to 
transfer the knowledge of their healthcare innovation, 12 of the 19 respondents reported 
that they were planning on licensing the product to a company (Figure 7) and 7 reported 
that they were considering starting up a spin-out company. Unsurprisingly academic 
publications were also a popular way of transferring knowledge (11 respondents).   
 
Question 6: Before this workshop, what would you consider to be your knowledge of 
health economics? 
Of the 19 respondents, five people reported that their knowledge of health 
HFRQRPLFVZDVµPHGLXP¶DQGSHRSOHDVµORZ¶7KHRWKHUSHRSOHUHported that their 
previous knowledge of health economics was non-existent. None of the respondents 
UHSRUWHGWKDWWKHLUKHDOWKHFRQRPLFVNQRZOHGJHZDVµH[SHUW¶RUµKLJK¶ 
 
Question 7: How do you normally demonstrate the value of your work to research 
funders and other investors?  
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Just one person reported that they normally performed a cost-effectiveness 
calculation when seeking to demonstrate the value of their work to funders or investors 
(Figure 8). The most popular way of demonstrating the value of an innovation was by 
quoting published data (15) followed by conducting clinical trials (7) and obtaining 
support from key opinion leaders (6).    
 
Question 8: How do you rate the following factors in influencing the decisions of your 
main research funders? 
The participants were asked to list their primary and secondary research funders 
and rate what they believed to be the priorities at funding assessment of their research 
funders. As the respondents were all from an engineering and science background, the 
main research funders for the participants were EPSRC (11) followed by EU (6). Other 
research funders were the Department of Health, the NHS National Institute for Health 
Research, research councils, and other public organisations. Only one participant reported 
that their research was supported by a company. Due to lack of funding application 
experiences, one participant missed this question. Of the 18 respondents, six people 
reported having one research funder only. 
Table 1 and Table 2 VKRZWKHSDUWLFLSDQWV¶SHUFHSWLRQVRIWKHSULRULWLHVRIWKHLU
primary and secondary research funders. It can be seen from this data that the participants 
believed that a number of issues were considered during the application process. There 
was a high degree of agreement between the respondents that the most important factor 
ZDVWKHµVFLHQWLILFTXDOLW\RIWKHSURSRVHGZRUN¶ZLWK16 out of 18 respondents rating this 
as either extremely or very important to their primary research funder and 11 out of 12 
for the secondary. The µVRFLDOLPSDFWRQKHDOWKFDUHDQGTXDOLW\RIOLIHLPSURYHPHQW¶ZDV
also viewed by the respondents as a high priority of research funders, being rated as 
either extremely or very important by 15/18 for the primary research funder and 10/12 for 
the secondary. The economic impact on the UK or EU was also recognised by 
participants. Of all the respondents, the primary funders were UK-based organisations 
and 14 of tKHUHVSRQGHQWVUDWHGWKHµHFRQRPLFLPSDFWRQ8.¶DVHLWKHUH[WUHPHO\RU
very important. 6 respondents reported that the EU was their secondary funder and all of 
WKHPUDWHGµHFRQRPLFLPSDFWRQ(8¶DVH[WUHPHO\LPSRUWDQW 
 
Question 9: What are your decision-making priorities when initiating innovative product 
development?  
/LNH UHVHDUFK IXQGHUV¶ SULRULWLHV D ODUJH QXPEHU RI IDFWRUV LQIOXHQFH WKH
academic community to innovate in healthcare (Table 3). Seventeen participants gave full 
responses to this question. For healthcare innovation, all of the respondents thought 
meeting clinical/patient needs are extremely or very important. Enthusiasm of a clinical 
expert for the product is also extremely or very important (14/17). Other factors like the 
availability of research funding are still the main driver of academic innovation with 15 
out of 17 respondents rating this as extremely or very important. Other factors such as 
scientific interest, the opinion of industrial partners, commercial opportunities and 
potential for short term success were seen as less important.  
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Question 10: How would you rate the MATCH HE tool for each of the following aspects? 
Eighteen participants provided their initial responses to the MATCH HE tool. 
The tool was rated as easily learnt by 16 of the 18 respondents, 17 of the respondents 
stated that the output from the tool was clear with 14 reporting that they understood the 
output. The breakeven analysis option in the tool was reported as useful by 14 of the 18 
participants.   
 
Figure 6 µ3OHDVHVHOHFWWKHSRWHQWLDOLPSDFWRI\RXUUHVHDUFKRQKHDOWKFDUHtick all that 
apply¶Q 19) 
 
Figure 7 µ+RZGR\RXSODQWRWUDQVIHU\RXUNQRZOHGJHtick all that apply"¶Q 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Figure 8 µ+RZGR\RXQRUPDOO\GHPRQVWUDWHWKHYDOXHRI\RXUZRUNWRUHVHDUFKIXQGHUV
and other investors? (tick all that apply¶Q=19) 
 
 
 
 
 
Table 1 Priorities of primary funder for funding assessment (n=18) 
 
Extremely 
important  
Very 
important 
Moderately 
important  
Slightly 
important 
Not at all 
important 
Scientific quality of 
proposed work 
9 7 2 0 0 
Your own academic 
reputation 
3 14 0 1 0 
Social impact on healthcare 
and quality of life 
improvement 
6 9 3 0 0 
Economic impact on UK 9 5 3 1 0 
Economic impact on EU 3 5 5 4 1 
Potential for short term 
benefits (3-5yrs) 
2 5 8 2 1 
 
 
   
 
   
   
 
   
   
 
   
    Title    
 
    
 
 
   
   
 
   
   
 
   
       
 
Table 2 Priorities of secondary funder for funding assessment (n=12) 
 
Extremely 
important  
Very 
important 
Moderately 
important  
Slightly 
important 
Not at all 
important 
Scientific quality of 
proposed work 
6 5 1 0 0 
Your own academic 
reputation 
4 4 3 1 0 
Social impact on healthcare 
and quality of life 
improvement 
7 3 2 0 0 
Economic impact on UK 4 2 5 1 0 
Economic impact on EU 8 1 1 2 0 
Potential for short term 
benefits (3-5yrs) 
1 8 2 1 0 
 
Table 3 ³:KDW DUH \RXU GHFLVLRQ-making priorities when initiating innovative product 
GHYHORSPHQW"´Q  
 
Extremely 
important 
Very 
important 
Moderately 
important 
Slightly 
important 
Not at all 
important 
Opinion of Industrial 
partners 
4 9 3 0 1 
Commercial opportunities 3 6 6 2 0 
Availability of research 
funding 
10 5 2 0 0 
Enthusiasm of clinical 
expert for the product 
7 8 2 0 0 
Scientific interest 7 6 3 1 0 
Potential for short term 
success 
1 4 4 6 2 
Opportunity to further 
career reputation 
3 4 6 3 1 
Meeting clinical/patient 
needs 
8 9 0 0 0 
4. Discussion 
The objective of this paper is to propose that a health economics based method can aid 
early decision making in healthcare technology development in academia. A secondary 
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objective is to investigate how this approach might fit into academic innovation and the 
response of the academic community to it.  
A variety of academic staff with a range of research experiences attended the 
+HDOWK (FRQRPLFV ZRUNVKRS $V WKH ZRUNVKRS ZDV HQWLWOHG µ$VVHVVLQJ DQG
GHPRQVWUDWLQJ WKH YDOXH RI \RXU +HDOWKFDUH 7HFKQRORJ\¶ WKLV suggests that the 
commercialisation of research innovations is a priority to a variety of academic staff and 
not restricted to particular specialties or grades of staff. Our position, described earlier in 
this paper, that commercialisation of healthcare innovations is a priority for UK 
universities, is also supported by the attendance of a number of knowledge transfer 
specialists.  
Previous knowledge of health economics amongst the attendees was relatively 
low, which supports our hypothesis that health economics is a relatively new area to 
academic staff involved in the development of healthcare technologies. Only one person 
out of the 19 attendees had previous experience of health economic assessment.   
The results of the questionnaire, as well as the informal responses of the 
participants during the workshop, show that this group of academics was enthusiastic 
about potentially integrating health economics into their research assessment. The 
positive responses to this new technique were likely to be due to some extent to the 
backgrounds of the audience. The majority of the attendees had science and engineering 
backgrounds and, therefore, can be assumed to be highly numerate, meaning that they 
were likely to find the theory and concepts behind Heath Economic modeling relatively 
straightforward.   
The questionnaire results provide support for our hypothesis that health 
economics has a valuable contribution to make to academic healthcare innovation. Most 
of the innovations described by the respondents were focused on the effectiveness part of 
the cost-effectiveness analysis, with only a small number reporting that their innovation 
would be cheaper than products on the market (it is a reasonable assumption that the rest 
will be more expensive). This suggests that for most healthcare innovations some sort of 
cost-effectiveness calculation will be needed to persuade purchasers, investors or funders 
that the additional patient benefits are worth the increased cost of the innovation. As 
stated earlier, health economics is increasingly being used by these stakeholders to aid 
purchasing and investment decisions.   
In terms of commercialisation plans, the majority of the respondents reported 
that they were planning on either licensing their product to a company or starting a spin-
out company. In these instances cost-effectiveness analysis would be valuable in assisting 
decision making during commercial product development, further supporting our 
assertion that health economics can benefit healthcare innovations from the very early 
stages, and throughout development. The fact that the majority of the attendees reported 
that the ability to perform a breakeven analysis would be useful is further evidence in 
support of our hypothesis that health economics methods can benefit academic 
innovators.  The academics in our study reported that quoting published data is still the 
main method of demonstrating the value of the academic innovation to research funders 
and that they believe that the scientific quality is still the primary priority for research 
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funders. However, they also reported that social and economic impact is growing in 
importance for research funding assessment and this further supports for the need for an 
effective technique to demonstrate and evaluate the trade-off of the innovation between 
cost and effectiveness.  
The respondents reported that there are a large number of priorities for their 
research funders and that they believe that research funders place a lot of importance on 
the social impact of healthcare and quality of life improvements when funding research. 
This suggests that academic innovators have to focus on a number of different issues 
when preparing funding applications, which is very challenging. The provision of a 
relatively easy to learn and accessible tool could assist academic innovators in 
performing early stage health economic calculations. The MATCH HE tool has been 
designed to carry out basic cost-effectiveness analysis for the people who have little or no 
experience in health economics (Craven et al., 2009). The questionnaire data indicates 
that the MATCH HE tool and its outputs are readily understandable and usable by 
academic healthcare innovators.  
The questionnaire study was an exploratory investigation, with a small and self-
selected sample from one institution, and as such we must be wary of generalising the 
results from this study to the wider academic community. In addition, we acknowledge 
that the University of Nottingham is affiliated with a large NHS acute trust and as a 
result, healthcare innovation is likely to be a particularly important research theme for 
this institution. 
However this work backs up the findings of our previous case studies with 
SMEs, many of which are university spin-outs, that demonstrated the value of such an 
evaluation tool in informing QHZ SURGXFW GHYHORSPHQW E\ HQFRXUDJLQJ µVWDJH-gate 
WKLQNLQJ¶)XUWKHUPRUHSRVWJUDGXDWHFRXUVHVLQHQJLQHHULQJGHSDUWPHQWVDUHLQFUHDVLQJO\
stressing the need to consider not only the technology that makes up a device, but also the 
part the device will play in the patient pathway, and how it will be assessed by health 
providers.  
 
5. Conclusions 
We have proposed a method of aiding decision-making for new healthcare technologies 
developed within academia. This is based upon applying health economics at an early 
stage in the product development process. This offers both academic and technology 
transfer staff the opportunity to assess which technologies are likely to provide the 
greatest impact on healthcare. It is also a useful approach when demonstrating the value 
of the technology to research funders and potential investors. 
A working knowledge of health economics should benefit academic researchers 
working on the design of healthcare innovations. The next stage of this work will be 
validating the use of the MATCH HE tool by academics in the laboratory i.e. at a stage in 
the R&D process that is prior to formation of a spin-out company. 
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 In addition, we will further develop the MATCH HE tool, and its training, to 
ensure that it fully meets the needs of users with little prior knowledge of health 
technology assessment. 
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